4.6 Review

A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide

期刊

ANNALS OF MEDICINE
卷 54, 期 1, 页码 2078-2088

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/07853890.2022.2101689

关键词

Budesonide; eosinophilic esophagitis; meta-analysis

资金

  1. National Natural Science Foundation of China [81973754]
  2. Shaanxi University of Traditional Chinese Medicine Innovation Team Project [2019-QN06]

向作者/读者索取更多资源

This study updated the clinical efficacy and safety of budesonide in the treatment of eosinophilic esophagitis using high-quality randomized controlled trial results, showing that oral budesonide is superior to placebo in terms of efficacy. Additionally, it was found that the efficacy of budesonide in patients is not dose-dependent.
Objective Eosinophilic esophagitis (EoE) is a chronic, local immune-mediated inflammatory oesophageal disease. Although Budesonide is recommended as one of the first-line drugs for EoE treatment, its efficacy is still controversial in multiple studies. Due to the continuous emergence of new and reliable research evidence in recent years, we updated the meta-analysis using RCT trial results to evaluate the efficacy and safety of budesonide. Materials and method Retrieve the data of the randomised controlled trial literature from 2000 to June 20, 2021, on using Budesonide in the treatment of eosinophilic esophagitis from the three major databases. Based on the results achieved with the Cochrane risk assessment tool, evaluate the quality of the included literature to extract the data, and perform the Meta-analysis with RevMan5.4 and Stata15.0. Results A total of 958 articles were retrieved, with 10 articles finally included, thus forming a sample size of 712 cases. The main outcome indicators of the meta-analysis are as follows: (1) Histological remission: the Budesonide group performs better than the placebo control group when it comes to histological remission of injuries [RR = 23.82, 95%CI = (13.46, 42.21), p < .001]; (2) Eosinophil count: the Budesonide group is superior to the control group in terms of reduced eosinophil count [SMD = -1.34, 95%CI = (-1.52, -1.15), p < .001]. Conclusion More and more high-quality randomised controlled trials show that oral budesonide in the treatment of eosinophils esophagitis was better than the placebo group. Mounting high-quality RCTs have confirmed the efficacy of oral budesonide in the treatment of eosinophilic esophagitis and that the effects of this drug may not be so dose-dependent. It is safe to take budesonide for a long time, and this drug is a relatively ideal option for drug treatment of eosinophilic esophagitis at present, so it is worthy of clinical application. Key Messages We used high-quality randomised controlled trials to meta-update the previous results to further confirm the clinical efficacy and safety of budesonide. Oral budesonide in the treatment of eosinophilic esophagitis is significantly better than the placebo control group. We have confirmed the value of its clinical application and promotion by including more high-quality randomised controlled trials. We also found that the efficacy of budesonide in patients is not dose-dependent, and more research is needed to confirm this.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据